Antiviral agents for influenza: Molecular targets, concerns of resistance, and new treatment options

Current Drug Targets

Volumn 10, Issue 10, 2009, Pages 1041-1048

  Maltezou, Helen C ^a   Tsiodras, Sotirios ^b  

^a Hellenic Center for Disease Control and Prevention   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

A 315675; AMANTADINE; ANTIVIRUS AGENT; ARBIDOL; CS 8958; DAS 181; FAVIPIRAVIR; HEMAGGLUTININ; INFLUENZA VACCINE; OSELTAMIVIR; PERAMIVIR; PLACEBO; PROBENECID; PYRAZINE DERIVATIVE; RIBAVIRIN; RIMANTADINE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; ZANAMIVIR;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; AVIAN INFLUENZA; CLINICAL TRIAL; CROSS RESISTANCE; DISEASE SURVEILLANCE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; HEADACHE; HEALTH CARE PLANNING; HUMAN; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INHIBITION KINETICS; MEMBRANE FUSION; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; OTITIS MEDIA; PANDEMIC; PHENOTYPE; PRACTICE GUIDELINE; PUBLIC HEALTH; REVIEW; SEROCONVERSION; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; VIRUS SHEDDING; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTIVIRAL AGENTS; DISEASE OUTBREAKS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, VIRAL; HEALTH PLANNING; HUMANS; INFLUENZA, HUMAN; MUTATION; PUBLIC HEALTH;

EID: 70450174426     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009789577972     Document Type: Review

References (86)

1. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008; 52: 3284-3292
2. Maltezou HC. Nosocomial influenza: new concepts and practice. Curr Opin Infect Dis 2008; 21: 337-343
3. Hota S, McGear A. Antivirals and the control of influenza outbreaks. Clin Infect Dis 2007; 45: 1362-1368
4. Tang JW, Ngai KL, Wong JC, Lam WY, Chan PK. Emergence of adamantane-resistant influenza A(H3N2) viruses in Hong Kong between 1997 and 2006. J Med Virol 2008; 80: 895-901.
5. Deyde VM, Xu X, Bright RA, Shaw M, Smith CB, Zhang Y, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 2007; 196: 249-257 (Pubitemid 47047464)
6. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364: 759-765 (Pubitemid 39165094)
7. Bright RA, Medina MJ, Xu X, Wallis TR, Davis XM, Povinelli L, et al. Incidence of adamantaine resistance among influenza A(H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366: 1175-1181
8. Centers for Disease Control and Prevention, 2006. CDC recommends against the use of amantadine and rimantadine for the treatment or prophylaxis of influenza in the United States during the 2005-06 influenza season, available at: http://www.cdc.gov/flu/han011406.htm (last accessed: January 19, 2009).
9. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O. Oseltamivir- resistant influenza viruses A (H1N1), Norway, 2007-2008. Emerg Infect Dis 2009;15:155-162
10. Lackenby A, Thompson CI, Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Curr Opin Infect Dis 2008; 21: 626-638
11. Centers for Disease Control and Prevention, 2008. CDC issues interim recommendations for the use of influenza antiviral medications in the setting of oseltamivir resistance among circulating influenza A (H1N1) viruses, 2008-2009 influenza season, available at: http://www2a.cdc.gov/HAN/ArchiveSys/-ViewMsgV. asp?AlertNum=00279 (last accessed: January 19, 2009).
12. World Health Organization, 2008. Influenza A (H1N1) virus resistance to oseltamivir-last quarter 2007 to May 5, 2008, available at: http://www.who.int/ csr/disease/influenza/H1N1ResistanceWeb20080505. pdf ( last accessed: January 19, 2009).
13. Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, Hollingsworth TD, et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Science 2009; 324: 1557-1561
14. Meijer A, Lackenby A, Hay A, Zambon M. Influenza antiviral susceptibility, monitoring activities in relation to national antiviral stockpiles in Europe during the the winter 2006-2007 season. Euro surveill 2007; 12
15. World Health Organization, 2005. Antiviral drugs: their role during a pandemic, available at: http://www.who.int/csr/disease/-avian-influenza/ antivirals2005-11-3/en/ (last accessed: January 19, 2009).
16. World Health Organization, 2007. WHO Interim Protocol: rapid operations to contain the initial emergence of pandemic influenza (updated October 2007), available at: http://www.who.int/csr/disease/avian-influenza/guidelines/ RapidContProtOct15.pdf (last accessed: January 19, 2009).
17. Centers for Disease Control and Prevention (CDC). Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 433-435
18. Tsiodras S, Mooney JD, Hatzakis A. Role of combination antiviral therapy in pandemic influenza and stockpiling implications. BMJ 2007; 334: 293-294
19. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 2006;70:121-131
20. Maltezou HC, Drancourt M. Nosocomial influenza in children. J Hosp Infect 2003; 55: 83-91.
21. Hay AJ, Zambon MC, Wolstenholme AJ, Skehel JJ, Smith MH. Molecular basis of resistance of influenza A viruses to amantadine. J Antimicrob Chemother 1986;18 (Suppl B):19-29. (Pubitemid 17199048)
22. Abed Y, Goyette N, Boivin G. Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations. Antimicrob Agents Chemother 2005; 49: 556-559 (Pubitemid 40175661)
23. Stilianakis NI, Perelson AS, Hayden FG. Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. J Infect Dis 1998; 177: 863-873
24. Rahman M, Bright RA, Kieke BA, Donahue JG, Greenlee RT, Vandermause M, et al. Adamantane-resistant influenza infection during the 2004-2005 season. Emerg Infect Dis 2008; 14: 173-176
25. Schunemann HJ, Hill SR, Kakad M, Bellamy R, Uyeki TM, Hayden FG, et al. WHO rapid advice guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 2007; 7: 21-31. (Pubitemid 44932137)
26. Cheung C-L, Rayner JM, Smith GD, Wang P, Naipospos TS, Zhang J, et al. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis 2006; 193: 1626-1629 (Pubitemid 43839465)
27. Tumpey TM, Garcia-Sastre A, Mikulasova A, Taubenberger JK, Swayne DE, Palese P, et al. Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci 2002; 99: 13849-13854
28. Zurcher T, Yates PJ, Daly J, Sahasrabudhe A, Walters M, Dash L, et al. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro. J Antimicrob Chemother 2006; 58: 723-732 (Pubitemid 44390944)
29. Hayden FG. Antivirals for influenza: historical perspectives and lessons learned. Antiviral Res 2006; 71: 372-378 (Pubitemid 44226490)
30. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163: 1667-1672 (Pubitemid 36898954)
31. Sugaya N, Tamura D, Yamazaki M, Ichikawa M, Kawakami C, Kawaoka Y, et al. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis 2008; 47: 339-345 (Pubitemid 352009352)
32. Baz M, Abed Y, McDonald J, Boivin G. Characterization of multi-drug resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 2006; 43: 1555-1561 (Pubitemid 44901897)
33. World Health Organization. Influenza A(H1N1) virus resistance to oseltamivir - Last quarter 2007 to 4 April 2008, available at: http://www.who.int/csr/disease/influenza/H1N1ResistanceWeb20080403.pdf (last accessed: January 19, 2009).
34. Ives JA, Carr JA, Mendel DB, Tai CY, Lambkin R, Kelly L, et al. The H274Ymutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002; 55: 307-317 (Pubitemid 34718130)
35. Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, Klimov A, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrb Agents Chemother 2006; 50: 2395-2402 (Pubitemid 43993177)
36. Ferraris O, Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol 2008; 41: 13-19 (Pubitemid 350298978)
37. Van der Vries E, van der Berg B, Schutten M. Fatal oseltamivir-resistant influenza virus infection. New Engl J Med 2008; 359: 1074-1076
38. Englund JA, Champlin RE, Wyde PR, Kantarjian H, Atmar RL, Tarrand J, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998; 26: 1418-1424 (Pubitemid 28270175)
39. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998; 178: 1257-1262 (Pubitemid 28523261)
40. Abed Y, Baz M, Boivin G. A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus. J Infect Dis 2009; 199: 180-183
41. Hurt AC, Ho H, Barr I. Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors. Expert Rev Anti Infect Ther 2006; 4: 795-805. (Pubitemid 44890619)
42. Moscona A. Oseltamivir resistance-disabling our influenza defenses. N Engl J Med 2005; 353: 2667-2672 (Pubitemid 41817709)
43. Hayden FG. Antiviral resistance in influenza viruses. Implications for management and pandemic response. New Engl J Med 2006; 354: 785-788
44. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353: 1363-1373
45. De Jong MD, Than TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353: 2667-2672 (Pubitemid 41817715)
46. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005; 437: 1108. (Pubitemid 41509341)
47. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, de Jong MD, et al. Update on avian influenza A (H5N1) virus infection in humans. Writing committee of the second World Health Organization consultation on clinical aspects of human infection with avian influenza A (H5N1) virus. N Engl J Med 2008; 358: 261-273
48. McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg Infect Dis 2007; 13: 1354-1357
49. Rameix-Welti MA, Agou F, Buchy P, Mardy S, Aubin JT, Véron M, et al. Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir. Antimicrob Agents Chemother 2006; 50: 3809-3815 (Pubitemid 44684897)
50. Influenza Team, European Centre for Disease Prevention and Control. Avian influenza update: recent outbreaks of H5N1 in poultry worldwide. Euro Surveill 2007; 12: E070125.2.
51. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360; 2605-2615
52. Gani R, Hughes H, Fleming D, Griffin T, Medlock J, Leach S. Potential impact of antiviral drug use during influenza pandemic. Emerg Infect Dis 2005; 11: 1355-1362 (Pubitemid 41209127)
53. Balicer RD, Huerta M, Davidovitch N, Grotto I. Cost-benefit of stockpiling drugs for influenza pandemic. Emerg Infect Dis 2005; 11: 1280-1282 (Pubitemid 41045338)
54. World Health Organization. Pandemic influenza draft protocol for rapid response and containment. May 30, 2006, available at www.who.int/crs/disease/ avian-influenza/guidelines/protocolfinal30-05-06a.pdf (last accessed: January 19, 2009).
55. Lee, VJ, Phua, KH, Chen MI, Chow A, Ma S, Goh KT, et al. Economics of neuraminidase inhibitor stockpiling for pandemic influenza, Singapore. Emerg Infect Dis 2006; 12; 95-102. (Pubitemid 43143543)
56. Calfee DP, Peng AW, Cass LM, Lobo M, Hayden FG. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother 1999; 43: 1616-1620 (Pubitemid 29331237)
57. Bantia S, Arnold CS, Parker CD, Upshaw R, Chand P. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res 2006; 69: 39-45. (Pubitemid 41790480)
58. Sidwell RW, Bailey KW, Morrey JD, Wong MH, Maldwin TJ, Smee DF. Inhibition of influenza virus infections in immunosuppressed mice with orally administered peramivir (BCX-1812). Antiviral Res 2003; 60: 17-25.
59. Mishin VP, Hayden FG, Signorelli KL, Gubareva LV. Evaluation of methyl inosine monophosphate (MIMP) and peramivir activities in a murine model of lethal influenza A virus infection. Antiviral Res 2006; 71: 64-68
60. Barroso L, Treanor J, Gubareva L, Hayden FG. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther 2005; 10: 901-910 (Pubitemid 43076341)
61. Kohno S, et al. "A Double-Blind, Placebo-Controlled Study of Intravenous Peramivir in Acute Influenza Patients" ICAAC-IDSA 2008; Abstract V-4154a.
62. Boltz DA, Ilyushina NA, Arnold CS, Babu YS, Webster RG, Govorkova EA. Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. Antiviral Res 2008; 80: 150-157
63. Abed Y, Nehme B, Baz M, Boivin G. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. Antiviral Res 2008; 77: 163-166
64. Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005; 49: 4515-4520
65. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 2009; 53: 186-192
66. Sidwell RW, Huffman JH, Barnard DL, Bailley KW, Wong MH, Morrison A, et al. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res 1998; 37: 107-120 (Pubitemid 28186301)
67. Takahashi K, Furuta Y, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, et al. In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir Chem Chemother 2003; 14: 235-241
68. Belser JA, Lu X, Szretter KJ, Jin X, Aschenbrenner LM, Lee A, et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 2007; 196: 1493-1499
69. Malakhov MP, Aschenbrenner LM, Smee DF, Wandersee MK, Sidwell RW, Gubareva LV, et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006; 50: 1470-1479
70. Shi L, Xiong H, He J, Deng H, Li Q, Zhong Q, et al. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch Virol 2007; 152: 1447-1455 (Pubitemid 47124957)
71. Leneva IA, Fediakina IT, Guskova TA, Glushkov RG. [Sensitivity of various influenzax virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A]. Ter Arkh 2005; 77: 84-88 [article in Russian].
72. Boriskin YS, Leneva IA, Pécheur EI, Polyak SJ. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem 2008; 15: 997-1005.
73. Chen Y, Qin K, Wu WL, Li G, Zhang J, Du H, et al. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes. J Infect Dis 2009; 199: 49-58.
74. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 2008; 3: e3942.
75. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145: 599-609.
76. Hayden F. Developing new antiviral agents for influenza treatment; what does the future hold? Clin Infect Dis 2009; 48: S3-13.
77. Masihi KN, Schweiger B, Finsterbusch T, Hengel H. Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice. J Chemother 2007; 19: 295-303. (Pubitemid 47075125)
78. Morrison D, Roy S, Rayner C, Amer A, Howard D, Smith JR, et al. A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination. PloS One 2007; 2: e1305.
79. Holodniy M, Penzak SR, Straight TM, Davey RT, Lee KK, Goetz MB, et al. Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Antimicrob Agents Chemother 2008; 52: 3013-3021
80. Govorkova EA, Fang HB, Tan M, Webster RG. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother 2004; 48: 4855-4863 (Pubitemid 39577694)
81. Ison MG, Gnann JW Jr, Nagy-Agren S, Treannor J, Paya C, Steigbigel R, et al. Safety and efficacy of nebulized zananivir in hospitalized patients with serious influenza. Antivir Ther 2003; 8: 183-190 (Pubitemid 36960891)
82. Wu JT, Leung GM, Lipsitch M, Cooper BS, Riley S. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Med 2009; 6: e1000085.
83. Hayden FG, Douglas RG, Simons R. Enhancement of activity against influenza viruses by combinations of antiviral agents. Antimicrob Agents Chemother 1980; 18: 536-541 (Pubitemid 11224626)
84. Smee DF, Wong MH, Baily KW, Sidwell RW. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses. Antivir Chem Chemother 2006; 17: 185-192
85. McCaw JM, Wood JG, McCaw CT, MvVernon J. Impact of emerging antiviral drug resistance on influenza containment and spread: influence of subclinical infection and strategic use of a stockpile containing one or two drugs. PloS One 2008; 3: e2362.
86. Russell CA, Jones TC, Barr IG, Cox NJ, Garten RJ, Gregory V, et al. Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza strains. Vaccine 2008; 26S: D31-4.